QPS partners Taiwan’s DCB and extends offering

By Gareth Macdonald

- Last updated on GMT

Related tags Venture capital Pharmacology

US contract research organisation (CRO) QPS has been called in by the Taiwanese Development Center for Biotechnology (DCB) to provide support services for biotech firms operating in the region.

The new alliance is part of the “biotechnology take-off package” that Taiwan’s government launched in March in a bid to double the value of the country’s NT$150bn (€3.3bn) a year biotechnology sector.

A central focus of this initiative was to reform the non-profit making DCB, placing a greater emphasis on its role in drug R&D and particularly in preclinical development and early-stage safety testing.

As a result, QPS stands to benefit twofold from the partnership, gaining customers for its development business as well as adding chemistry, manufacturing and controls (CMC), toxicology and pharmacology testing to its wider service offering.

Although the two organisations have worked together successfully on a project-by-project basis for several years, the new strategic partnership will provide additional benefits according to DCB president Chia Lin Jeff Wang.

Dr Wang explained that the “alliance with QPS will not only provide…integrated, international-standard preclinical testing services to domestic and pharmaceutical companies, but also lead to new clients and expanded business opportunities for DCB in the international drug development arena​.”

QPS CEO Ben Chien was also positive about the alliance, suggesting that it provides “even more efficiencies of scale [and will help] to increase speed and reduce costs while maintaining our focus on accuracy of data.”

Singapore and Taiwan team up?

The wider aim of the government biotech package is to drive the sector to an annual value of more than NT$12tn over the next ten years through the creation a NT$60bn venture capital fund and the “Supra Incubator Center” for start-ups.

Other measures covered by the initiative include the foundation of an agency similar to the US Food and Drug Administration (FDA), the construction of a biotech park in Chupei in the north of the country and a doubling of the DCB’s workforce.

While clearly ambitious the Taiwanese efforts are not without precedent, the most obvious example being Singapore which has attracted major global players like Lonza, GSK and Genentech thanks to a decade long investment in the industry.

Indeed, when Minister Chang Chin-fu announced the Taiwanese take-off package in the spring he suggested that increased co-operation generate additional international business for both countries.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more